Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05763693
Other study ID # 21-34232
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date July 31, 2024
Est. completion date July 31, 2027

Study information

Verified date November 2023
Source University of California, San Francisco
Contact Elodie Lebas, RN
Phone (415) 476-1442
Email elodie.lebas@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nearly half of child deaths occur during the neonatal period, and 80% of those occur in babies with low birthweight. Although tremendous progress has been made towards reducing under-five mortality globally, declines in neonatal mortality lag behind those observed in older children. Low birthweight babies are at increased risk of poor outcomes compared to those who are term-appropriate for gestational age, including mortality, stunting, and growth failure. Recent evidence has demonstrated that the incidence of wasting and linear growth failure is highest between birth and 3 months of age, substantially earlier than previously thought. Interventions are urgently needed to improve outcomes in low birthweight babies; however, these interventions must not interfere with breastfeeding and thus some well-established interventions used to treat or prevent malnutrition in older children cannot be considered. The investigators recently demonstrated that biannual mass azithromycin distribution reduces all-cause childhood mortality by approximately 25% in infants aged 1-5 months, with stronger effects seen in underweight infants. This study did not include neonates due to the risk of infantile hypertrophic pyloric stenosis (IHPS) that has been hypothesized to be associated with macrolide use during early infancy. However, our study team documented only a single case of IHPS among 21,833 neonates enrolled in a trial of azithromycin versus placebo administered to neonates aged 8-27 days for prevention of infant mortality, documenting no major risk of IHPS associated with azithromycin. Here, the investigators propose an individually randomized trial where participants will receive a single oral dose of azithromycin (administered either during the neontal period or 21 days after enrollment), two does of oral azithromycin spaced 21 days apart, or two doses of placebo to evalute if azithromycin improves nutritional outcome and reduces infectious burden among neonates aged 1-27 days who are either low birthweight (<2500 g at birth) or underweight (weight-for-age Z-score < -2 at enrollment). The primary outcome will be weight-for-age Z-score at 6 months of age compared between arms. The investigators anticipate that the results of this study will provide definitive evidence on azithromycin as an early intervention for low birthweight/underweight neonates, who are at the highest risk of adverse outcomes.


Description:

The Vitality in Infants Via Azithromycin for Neonates Trial (VIVANT) is a proposed 1:1:1:1 randomized placebo-controlled trial to determine whether a single oral dose of azithromycin (20 mg/kg) administered either in the early or late neonatal/early infancy period is effective for improving infant growth outcomes, and if there is additional benefit of administration of a second dose of azithromycin 21 days after the first dose (Figure 2). This intervention schedule will allow for several questions related to azithromycin administration in neonates to be answered efficiently, including: 1. A single oral azithromycin dose compared to placebo, administered either earlier or later during the neonatal period or early infancy. 2. Two oral doses of azithromycin spaced 21 days apart compared to placebo. 3. Two oral doses of azithromycin compared to a single oral dose of azithromycin, which would allow for determination of any dose-dependent effects. 4. An early dose of azithromycin compared to a later dose of azithromycin, which may be beneficial if administration of azithromycin earlier during the neonatal period increases risk of IHPS


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5000
Est. completion date July 31, 2027
Est. primary completion date July 31, 2027
Accepts healthy volunteers No
Gender All
Age group 1 Day to 27 Days
Eligibility Inclusion Criteria: - Aged 1-27 days old - Birthweight < 2500 g and/or weight-for-height Z score <- 2 standard deviations at enrollment - Weigh at least <1500 g at time of enrollment - Able to feed orally - Family intends to stay in the study area for at least 6 months - Appropriate consent from at least one caregiver - No known allergy to macrolides - No hepatic failure manifested by neonatal jaundice - Not currently an inpatient at the clinic - Not being transferred to a hospital for clinical complications Exclusion Criteria: - Birthweight > 2500 g - Weigh less than 1500 g at time of enrollment - Unable to feed orally - Family planning to move within 6 months - Mother/ caregiver not willing to participate - Allergic to macrolides - Hepatic failure manifested by neonatal jaundice - Currently being seen as an inpatient at the clinic - Currently being transferred to a hospital for clinical complications

Study Design


Intervention

Drug:
Azithromycin at Baseline
this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
Azithromycin at Day 21
this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
Other:
Placebo at Baseline
this group will be randomized to receive Placebo at baseline
Placebo at Day 21
This group will be randomized to receive Placebo at the day 21 visit

Locations

Country Name City State
Burkina Faso Centre de Recherche en santé de Nouna Nouna

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Centre de Recherche en Sante de Nouna, Burkina Faso

Country where clinical trial is conducted

Burkina Faso, 

Outcome

Type Measure Description Time frame Safety issue
Primary weight gain at 6 month of age Weight for Age Z score 6 months
Secondary IHPS Signs of IHPS will be screened at the 21 day follow up visit. diagnosed cases of IHPS will be reported by arm 21 days
Secondary Mortality at 6 months Vital status will be verified at each follow up visit 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Completed NCT04568889 - Minnesota COVID-19 Testing Project N/A
Completed NCT06063330 - Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects Phase 1
Completed NCT01198925 - Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion Phase 4
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Not yet recruiting NCT03636711 - Antibiotic Stewardship in Infectious Disease Departement
Completed NCT03457688 - Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children N/A
Completed NCT03241355 - Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children N/A
Terminated NCT05420077 - Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 Phase 1
Completed NCT04084106 - Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota Phase 4
Recruiting NCT05013944 - AnovaOS Network Powered Patient Registry
Completed NCT03893279 - Perception of Smell and Taste During Antibiotic Treatment
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Completed NCT01772901 - Brief Influenza Vaccine Education to Pregnant Women N/A
Completed NCT05413772 - Temocillin in ESBL-Enterobacteriaceae Infections
Completed NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Completed NCT04613271 - Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia Phase 3
Completed NCT03239665 - Vaccination Education Through Pharmacists and Senior Centers (VEPSC) N/A
Completed NCT03224026 - Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
Not yet recruiting NCT06102070 - Genetic Susceptibility to Severe Infections